Human CD34+-derived plasmacytoid dendritic cells as surrogates for primary pDCs and potential cancer immunotherapy

Human CD34+-derived plasmacytoid dendritic cells as surrogates for primary pDCs and potential cancer immunotherapy

IntroductionPlasmacytoid dendritic cells (pDCs) are capable of triggering broad immune responses, yet, their scarcity in blood coupled to their reduced functionality in cancer, makes their therapeutic use for in situ activation or vaccination challenging. MethodsWe designed an in vitro differentiati...

Full description

Bibliographic Details
Main Authors: Giovanna Fiore, Wolfgang Weckwarth, Kerstin Paetzold, Llucia Albertí Servera, Manuela Gies, Jakob Rosenhauer, Martina Antoniolli, Sina Nassiri, Stephan Schmeing, Steffen Dettling, Bhavesh Soni, Meher Majety, Anne B. Krug, Sabine Hoves, Monika Julia Wolf
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Immunology
Subjects:
dendritic cell differentiation
hematopoietic stem cells (HSCs)
human
DC vaccination
cancer immunotherapy
plasmacytoid dendritic cells (pDCs)
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1433119/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1433119/full

Similar Items